Doctors reveal hidden danger for some Ozempic, Wegovy users with brain disorders

Key Points:

• Neurologists warn that popular weight-loss drugs, specifically GLP-1 agonists like semaglutide, may accelerate disease progression in patients with neurodegenerative conditions such as ALS by causing rapid weight loss.
• While GLP-1 medications are effective for managing diabetes and obesity and offer protective effects against cardiovascular and liver diseases, weight loss can be detrimental for ALS patients who require maintaining or gaining weight to preserve nerve and muscle function.
• A 2025 case report highlighted a 52-year-old ALS patient whose condition rapidly worsened after losing 25 pounds on semaglutide, with stabilization observed after discontinuing the drug, underscoring the need for caution in prescribing these medications to ALS patients.
• Experts emphasize the importance of individualized treatment approaches for ALS patients, weighing the benefits of GLP-1 drugs against potential risks to neurodegenerative disease progression.
• Novo Nordisk, manufacturer of Ozempic and Wegovy, stated ALS and other neurodegenerative diseases are not listed adverse reactions for their semaglutide products and affirmed their commitment to patient safety and monitoring adverse event reports.